The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock

13 Nov 2023 16:00

Arix Bioscience PLC (ARIX) Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock 13-Nov-2023 / 16:00 GMT/BST


 

The following amendment has been made to the “Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock” announcement released on 10/11/2023 at 08:00 GMT under EQS News ID 1770215.

 

Some definitions of the “Company” have been amended to reflect the defined name of the portfolio company, “Aura”, throughout the release.

 

All other information remains unchanged. The fully amended text is shown below:

 

Arix Bioscience plc

 

Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock

 

LONDON, 13 November 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, notes that its Core Portfolio company, Aura Biosciences (NASDAQ: AURA) (“Aura”), has announced the closing of its underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $9.00 per share.

 

Aura received net proceeds from the Offering, after deducting the underwriting discounts and commissions and estimated offering expenses, of approximately $92.6 million. Aura intends to use the net proceeds from the Offering, together with its existing cash, cash equivalents and marketable securities to advance the clinical development of belzupacap sarotalocan for the treatment of choroidal melanoma and choroidal metastasis, to develop the platform and for general corporate purposes. Aura believes that the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, will enable it to fund its operating expenses and capital expenditure requirements into the second half of 2026.

 

Arix holds 1,508,483 shares in Aura. The holding value of these shares will continue to be determined by the market price of Aura’s shares.

 

The full text from Aura’s announcement can be accessed on the Aura Biosciences website here: https://ir.aurabiosciences.com/press-releases

 

[ENDS]

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

 

 

About Arix Bioscience plc

Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 


Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
ISIN:GB00BD045071
Category Code:MSCM
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:284573
EQS News ID:1772109
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
28th May 20214:56 pmEQSTransaction in own shares
27th May 20214:58 pmEQSTransaction in own shares
26th May 20214:53 pmEQSTransaction in own shares
25th May 20215:24 pmEQSTransaction in own shares
24th May 20215:04 pmEQSTransaction in own shares
21st May 20215:09 pmEQSTransaction in own shares
20th May 20215:27 pmEQSTransaction in own shares
20th May 20217:00 amEQSChange of registered office
19th May 20215:06 pmEQSTransaction in own shares
18th May 20215:33 pmEQSTransaction in own shares
18th May 20217:00 amEQSNotice of 2021 Annual General Meeting
17th May 20215:40 pmEQSTransaction in own shares
14th May 20215:02 pmEQSTransaction in own shares
13th May 20215:16 pmEQSTransaction in own shares
12th May 20215:12 pmEQSTransaction in own shares
12th May 20214:35 pmEQSAutolus to present additional data in AUTO1 in IBCL 
11th May 20215:43 pmEQSTransaction in own shares
10th May 20215:21 pmEQSTransaction in own shares
7th May 20215:19 pmEQSTransaction in own shares
6th May 20215:23 pmEQSTransaction in own shares
5th May 20215:16 pmEQSTransaction in own shares
4th May 20215:15 pmEQSTransaction in own shares
4th May 20217:00 amEQSTotal Voting Rights
30th Apr 20214:59 pmEQSTransaction in own shares
30th Apr 20217:00 amEQSOutcome of Strategic Implementation Review and Directorate Change
29th Apr 20215:10 pmEQSTransaction in own shares
28th Apr 20215:14 pmEQSTransaction in own shares
28th Apr 202112:02 pmEQSAmplyx Pharmaceuticals acquired by Pfizer
27th Apr 20215:29 pmEQSTransaction in own shares
27th Apr 20212:00 pmEQSLogicBio announces clinical and corporate updates
26th Apr 20215:32 pmEQSTransaction in own shares
23rd Apr 20215:11 pmEQSTransaction in own shares
22nd Apr 20215:15 pmEQSTransaction in own shares
21st Apr 20215:27 pmEQSTransaction in own shares
20th Apr 20215:31 pmEQSTransaction in own shares
19th Apr 20215:09 pmEQSTransaction in own shares
16th Apr 20215:18 pmEQSTransaction in own shares
15th Apr 20215:09 pmEQSTransaction in own shares
14th Apr 20215:13 pmEQSTransaction in own shares
13th Apr 20215:13 pmEQSTransaction in own shares
12th Apr 20215:23 pmEQSTransaction in own shares
9th Apr 20215:44 pmEQSTransaction in own shares
8th Apr 20215:28 pmEQSTransaction in own shares
8th Apr 20218:19 amRNSProactive One2One Virtual Investor Forum
8th Apr 20217:00 amEQSArix to Present at the Proactive One2One Virtual Investor Forum
7th Apr 20215:47 pmEQSTransaction in own shares
7th Apr 20217:00 amEQSArtios announces collaboration with Novartis to create next generation DDR cancer therapies 
6th Apr 20215:26 pmEQSTransaction in own shares
1st Apr 20215:20 pmEQSTransaction in own shares
1st Apr 20217:00 amEQSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.